282 related articles for article (PubMed ID: 15758787)
1. Economic costs of benign prostatic hyperplasia in the private sector.
Saigal CS; Joyce G
J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787
[TBL] [Abstract][Full Text] [Related]
2. Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association
Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
[TBL] [Abstract][Full Text] [Related]
3. The economic consequences of irritable bowel syndrome: a US employer perspective.
Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
[TBL] [Abstract][Full Text] [Related]
4. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
Shah M; Butler M; Bramley T; Curtice TG; Fine S
Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
[TBL] [Abstract][Full Text] [Related]
5. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.
Joish VN; Donaldson G; Stockdale W; Oderda GM; Crawley J; Sasane R; Joshua-Gotlib S; Brixner DI
Curr Med Res Opin; 2005 Apr; 21(4):535-44. PubMed ID: 15899102
[TBL] [Abstract][Full Text] [Related]
6. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.
Chang S; Long SR; Kutikova L; Bowman L; Finley D; Crown WH; Bennett CL
J Clin Oncol; 2004 Sep; 22(17):3524-30. PubMed ID: 15337801
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of treatment strategies for benign prostatic hyperplasia--is medical therapy more costly in the long run?
Saigal CS; Movassaghi M; Pace J; Joyce G;
J Urol; 2007 Apr; 177(4):1463-7; discussion 1467. PubMed ID: 17382755
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
Sasser AC; Rousculp MD; Birnbaum HG; Oster EF; Lufkin E; Mallet D
Womens Health Issues; 2005; 15(3):97-108. PubMed ID: 15894195
[TBL] [Abstract][Full Text] [Related]
9. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.
Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
Epilepsia; 2010 May; 51(5):838-44. PubMed ID: 20002150
[TBL] [Abstract][Full Text] [Related]
10. Cost of work-related injuries in insured workplaces in Lebanon.
Fayad R; Nuwayhid I; Tamim H; Kassak K; Khogali M
Bull World Health Organ; 2003; 81(7):509-16. PubMed ID: 12973643
[TBL] [Abstract][Full Text] [Related]
11. Healthcare expenditures for privately insured people with cystic fibrosis.
Ouyang L; Grosse SD; Amendah DD; Schechter MS
Pediatr Pulmonol; 2009 Oct; 44(10):989-96. PubMed ID: 19768806
[TBL] [Abstract][Full Text] [Related]
12. Urologic diseases in America project: benign prostatic hyperplasia.
Wei JT; Calhoun E; Jacobsen SJ
J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
[TBL] [Abstract][Full Text] [Related]
13. The impact of psoriasis on health care costs and patient work loss.
Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095
[TBL] [Abstract][Full Text] [Related]
14. The annual impact of seasonal influenza in the US: measuring disease burden and costs.
Molinari NA; Ortega-Sanchez IR; Messonnier ML; Thompson WW; Wortley PM; Weintraub E; Bridges CB
Vaccine; 2007 Jun; 25(27):5086-96. PubMed ID: 17544181
[TBL] [Abstract][Full Text] [Related]
15. Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
Wu EQ; Birnbaum HG; Mareva M; Tuttle E; Castor AR; Jackman W; Ruskin J
Curr Med Res Opin; 2005 Oct; 21(10):1693-9. PubMed ID: 16238910
[TBL] [Abstract][Full Text] [Related]
16. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
17. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.
Black L; Naslund MJ; Gilbert TD; Davis EA; Ollendorf DA
Am J Manag Care; 2006 Mar; 12(4 Suppl):S99-S110. PubMed ID: 16551208
[TBL] [Abstract][Full Text] [Related]
18. The burden of illness associated with renal cell carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
[TBL] [Abstract][Full Text] [Related]
19. Private health insurance plans in 1976: an evaluation.
Smith Carroll M
Soc Secur Bull; 1978 Sep; 41(9):3-16. PubMed ID: 102042
[TBL] [Abstract][Full Text] [Related]
20. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia.
Chirikos TN; Sanford E
J Urol; 1996 Apr; 155(4):1311-6. PubMed ID: 8632563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
